BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tendilla-Beltrán H, Flores G. Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19. Gen Hosp Psychiatry 2021;71:137-9. [PMID: 34045093 DOI: 10.1016/j.genhosppsych.2021.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Liberman JN, Pesa J, Petrillo MP, Ruetsch C. Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States. BMC Psychiatry 2022;22. [DOI: 10.1186/s12888-022-04026-7] [Reference Citation Analysis]
2 Costanza A, Amerio A, Aguglia A, Serafini G, Amore M, Hasler R, Ambrosetti J, Bondolfi G, Sampogna G, Berardelli I, Fiorillo A, Pompili M, Nguyen KD. Hyper/neuroinflammation in COVID-19 and suicide etiopathogenesis: Hypothesis for a nefarious collision? Neurosci Biobehav Rev 2022;136:104606. [PMID: 35289272 DOI: 10.1016/j.neubiorev.2022.104606] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Prokopez CR, Farinola R, Vallejos M, Lopredo LS, Sfriso LE, Chiapella LC, Arce C, Corral RM, Cuesta MJ, Alomo M. Olanzapine, risperidone and quetiapine: Do these atypical antipsychotics have a protective effect for SARS-CoV-2? Schizophrenia Research 2022. [DOI: 10.1016/j.schres.2022.01.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rivas-Ramírez ÁR, Tendilla-Beltrán H, Gómez-Mendoza LE, Loaiza G, Flores G. Patients with schizophrenia have decreased COVID-19 prevalence among hospitalised patients with psychiatric and neurological diseases: A retrospective analysis in Mexican population. Int J Clin Pract 2021;:e14528. [PMID: 34125988 DOI: 10.1111/ijcp.14528] [Cited by in F6Publishing: 3] [Reference Citation Analysis]